PLRX
PLIANT THERAPEUTICS, INC.Company Information
- Company Name
- PLIANT THERAPEUTICS, INC.
- CIK
- CIK0001746473
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- PLRX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- PLRX
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-01-20
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 138,058
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 44,962,946
- Shares outstanding
- 61,919,233
- Ownership
- 72.62%
Earnings Market Reaction
- Filing date
- 2026-08-11
- Price on filing date
- —
- 1-month reaction
- 12.62%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 25 | 22 | 45 | 94 | 87 | 92 | 71 | 80 | 80 | 114 | 63 | 58 | ||||||
| Short Term Investments | 133 | 149 | 145 | 148 | 176 | 214 | 285 | 325 | 356 | 368 | 431 | 466 | ||||||
| Prepaid Expense And Other Assets Current | 4 | 3 | 4 | 4 | 5 | 6 | 7 | 6 | 11 | 8 | 11 | 11 | ||||||
| Accounts Receivable Net Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Disposal Group Including Discontinued Operation Property Plant And Equipment Current | 1 | 1 | 1 | - | - | - | 0 | - | - | - | - | - | ||||||
| Assets Current | 163 | 175 | 196 | 246 | 267 | 311 | 362 | 410 | 448 | 490 | 506 | 534 | ||||||
| Income Taxes Receivable | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Property Plant And Equipment Net | 2 | 3 | 3 | 4 | 5 | 5 | 6 | 6 | 5 | 6 | 4 | 4 | ||||||
| Operating Lease Right Of Use Asset | 22 | 23 | 24 | 25 | 26 | 26 | 27 | 28 | 29 | 24 | 1 | 2 | ||||||
| Restricted Cash Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | ||||||
| Other Assets Noncurrent | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 190 | 203 | 225 | 277 | 300 | 345 | 397 | 446 | 484 | 522 | 512 | 540 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 2 | 0 | 0 | 0 | 1 | 6 | 6 | 7 | 3 | 7 | 5 | 3 | ||||||
| Accrued Liabilities Current | 4 | 4 | 10 | 8 | 7 | 7 | 12 | 10 | 8 | 6 | 10 | 8 | ||||||
| Operating Lease Liability Current | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 2 | ||||||
| Liabilities Current | 16 | 10 | 16 | 18 | 21 | 28 | 33 | 40 | 31 | 30 | 29 | 27 | ||||||
| Operating Lease Liability Noncurrent | 26 | 27 | 28 | 28 | 29 | 29 | 29 | 30 | 30 | 24 | 0 | 0 | ||||||
| Long Term Debt | 0 | 0 | 0 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 10 | 10 | ||||||
| Liabilities | 43 | 37 | 44 | 76 | 80 | 88 | 93 | 100 | 91 | 84 | 39 | 37 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 1,049 | 1,045 | 1,041 | 1,036 | 1,030 | 1,023 | 1,014 | 1,005 | 996 | 985 | 973 | 964 | ||||||
| Retained Earnings Accumulated Deficit | -902 | -879 | -859 | -836 | -810 | -766 | -710 | -660 | -603 | -547 | -500 | -459 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | -0 | 0 | -0 | 0 | 0 | 1 | -1 | -0 | 0 | -2 | ||||||
| Stockholders Equity | 147 | 165 | 181 | 200 | 220 | 257 | 304 | 346 | 393 | 437 | 474 | 503 | ||||||
| Liabilities And Stockholders Equity | 190 | 203 | 225 | 277 | 300 | 345 | 397 | 446 | 484 | 522 | 512 | 540 | ||||||
| Series A Junior Participating Preferred Purchase Rights | 0 | 0 | - | 0 | 0 | 0 | - | - | - | - | - | - | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | - | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | ||||||
| Common Stock Shares Issued | 62 | 62 | 61 | 61 | 61 | 61 | 61 | 61 | 60 | 60 | 60 | 60 | ||||||
| Shares Outstanding | 62 | 62 | 61 | 61 | 61 | 61 | 61 | 61 | 60 | 60 | 60 | 60 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialPLIANT THERAPEUTICS, INC. (PLRX) — SEC Financial Statements & Analysis
PLIANT THERAPEUTICS, INC. (PLRX) is a pharmaceutical preparations company, incorporated in DE. PLIANT THERAPEUTICS, INC. trades on Nasdaq as: PLRX. PLIANT THERAPEUTICS, INC. (PLRX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11. Based on that filing, PLIANT THERAPEUTICS, INC. carries a market cap of $70.59M, a P/E ratio of -0.76x, a P/B ratio of 0.48x, a P/S ratio of 3615.71x, an enterprise value of $44.22M, and an EV/EBITDA multiple of -0.46x. On profitability, it posts an operating margin of -78404.03%, a net margin of -68847.98%, a Return on Equity (ROE) of -50.29%, a Return on Assets (ROA) of -37.69%, and a Return on Invested Capital (ROIC) of -68.96%. Per share, it reports EPS of $-1.49, diluted EPS of $-1.49, free cash flow per share of $-1.14, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of -55.41% year-over-year, and EPS growth of -55.79% year-over-year. On the balance sheet, it maintains a current ratio of 9.90x, a quick ratio of 9.65x, working capital of $146.66M, a debt-to-equity ratio of 0.29x, a debt ratio of 0.23, an interest coverage ratio of -102.50x, free cash flow of $-70.89M (TTM), and net debt of $-26.36M. Figures sourced from SEC EDGAR.
- Market Cap
- $70.59M
- P/E TTM
- -0.76x
- EPS TTM
- $-1.49
- P/B TTM
- 0.48x
- ROE TTM
- -50.29%
- ROA TTM
- -37.69%
- Debt To Equity
- 0.29x
- Free Cash Flow TTM
- $-70.89M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is PLIANT THERAPEUTICS, INC. in?
PLIANT THERAPEUTICS, INC. (PLRX) operates in the Pharmaceutical Preparations industry.
What exchange does PLRX trade on?
PLIANT THERAPEUTICS, INC. (PLRX) trades on the Nasdaq.
Where is PLIANT THERAPEUTICS, INC. incorporated?
PLIANT THERAPEUTICS, INC. is incorporated in DE.
When was PLIANT THERAPEUTICS, INC. (PLRX)'s most recent SEC filing?
PLIANT THERAPEUTICS, INC. (PLRX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11.
What is PLRX's market cap?
PLIANT THERAPEUTICS, INC. (PLRX) has a market capitalization of $70.59M as of 2026-06-30.
What is PLRX's EPS (earnings per share)?
PLIANT THERAPEUTICS, INC. (PLRX)'s trailing twelve month EPS is $-1.49 as of 2026-06-30.
What is PLRX's ROE (return on equity)?
PLIANT THERAPEUTICS, INC. (PLRX)'s trailing twelve month Return on Equity (ROE) is -50.29% as of 2026-06-30.
What is PLRX's ROA (return on assets)?
PLIANT THERAPEUTICS, INC. (PLRX)'s trailing twelve month Return on Assets (ROA) is -37.69% as of 2026-06-30.
What is PLRX's ROIC (return on invested capital)?
PLIANT THERAPEUTICS, INC. (PLRX)'s trailing twelve month Return on Invested Capital (ROIC) is -68.96% as of 2026-06-30.
What is PLRX's EV/EBITDA?
PLIANT THERAPEUTICS, INC. (PLRX)'s trailing twelve month EV/EBITDA is -0.46x as of 2026-06-30.